In consultation with Consulting Editor, Dr. Samir Taneja, Dr. Sia Daneshmand has put together a state-of the-art issue of the Urologic Clinics devoted to Modern Management of Testicular Cancer. The issue focuses on surgical techniques and diagnostic modalities for testicular cancer. Clinical review articles are specifically devoted to the following: Imaging For Testicular Cancer; Management of Stage I Germ Cell Tumors; Management of Stage II Germ Cell Tumors; Current Management Of Disseminated GCT; Post-Chemotherapy Resection of Residual Mass in NSGCT; Indications For Surgery in Disseminated Seminoma; Growing Teratoma Syndrome; Management of The Primary Testicular Tumor; High-Dose Chemotherapy and Autologous Stem Cell Transplantation; mRna As Biomarkers For Germ Cell Tumors; Minimally Invasive RPLND: Is There a Role?; Complications of RPLND; Preservation of Fertility in Testis Cancer Management. Readers will come away with the latest information they need to optimize surgical and management outcomes in the patient with testicular cancer.

This book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.

This book addresses the most pressing current questions in the management of urologic malignancies. The rapid advances in imaging and molecular markers are placed into a clinical context, with explanation of their effects on prognosis and treatment planning. Similarly, progress in immunotherapy is carefully examined, focusing in particular on the role of immune checkpoint inhibitors in both early- and late-stage urologic malignancies. Looking beyond the improvements in minimally invasive techniques for urologic cancers, the impacts of care coordination pathways and enhanced recovery after surgery protocols are reviewed. Readers will also find enlightening discussion of the decision algorithm for the treatment of early-stage, high-grade bladder cancer, taking into account evidence on the most advanced treatment options and the circumstances in which surgery may need to be expedited. The penultimate chapter discusses the Cancer Genome Atlas project for bladder cancer, and the book closes by considering contemporary medical and surgical management of testicular cancer.